Abstract
The heterogeneous injury pathophysiology of traumatic brain injury (TBI) is a barrier to developing highly sensitive and specific diagnostic tools. Phage display, a protein‒protein screening technique routinely used in drug development, has the potential to be a powerful biomarker discovery tool for TBI. However, analysis of these large and diverse phage libraries is a bottleneck to moving through the discovery pipeline in a timely and efficient manner. This article describes a unique discovery pipeline involving domain antibody (dAb) phage in vivo biopanning and next-generation sequencing (NGS) analysis to identify targeting motifs that recognize distinct aspects of TBI pathology. To demonstrate this process, we conduct in vivo biopanning on the controlled cortical impact mouse model of experimental TBI at 1 and 7 days postinjury. Phage accumulation in target tissues is quantified via titers before NGS preparation and analysis. This phage display biomarker discovery pipeline for TBI successfully achieves discovery of temporally specific TBI targeting motifs and may further TBI biomarker research for other characteristics of injury.
Original language | English (US) |
---|---|
Article number | e67 |
Journal | Current Protocols |
Volume | 1 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2021 |
Keywords
- domain antibody fragment
- next generation sequencing
- phage display
- traumatic brain injury
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics(all)
- General Neuroscience
- General Immunology and Microbiology
- Health Informatics
- Medical Laboratory Technology
- General Medicine